A Closer Look at 4 Analyst Recommendations For Akoya Biosciences
Portfolio Pulse from Benzinga Insights
Four analysts have recently published ratings on Akoya Biosciences (NASDAQ:AKYA), showing a range of perspectives from bullish to somewhat bullish. The average 12-month price target has decreased by 33.29%, with a high estimate of $7.00 and a low estimate of $4.00. Analysts have lowered their price targets in response to the company's declining revenue and financial challenges.
August 06, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have provided mixed ratings for Akoya Biosciences, with a recent decrease in the average 12-month price target by 33.29%. The company's financial performance, including a 14.29% decline in revenue and high debt levels, has influenced these ratings.
The decrease in the average price target and the lowering of ratings by multiple analysts indicate a negative short-term outlook for Akoya Biosciences. The company's financial challenges, including declining revenue and high debt levels, are likely contributing factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100